Ushering in a new generation of cancer immunotherapies - simpler, safer and more effective.
May 28, 2015: PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy. PDS Biotechnology announces preliminary data showing that PDS0101, a cancer immunotherapy targeting HPV-16, generated strong T-cell responses in pre-cervical cancer patients.
December 15, 2014: NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology. NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’). Farad Azima, CEO, “This is an exceptional opportunity for NetScientific. As we stated in our recent results, we have been evaluating opportunities in the therapeutic space. PDS Biotechnology is at the forefront of cancer immunotherapies and by investing in the company, represents our entry into next generation therapeutics.”
October 2014: PDS CEO to present at the World Vaccine Congress, Belgium on October 13, 2014. Dr. Bedu-Addo will review the development of PDS’s clinical-stage HPV-cancer immunotherapy.
October 2014: PDS Scientist to present at AAPS, National Meeting, San Diego. Dr. M. Keough will be giving a talk on the Characterization of Immune Modulating Nanoparticles on November 6, 2014.
February 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101. The first patient has been successfully vaccinated with the PDS0101 cancer immunotherapy in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia.
November 1, 2013: PDS Biotechnology Initiates Phase 1 Human Clinical Trials for PDS0101. PDS has initiated patient recruitment for its HPV cancer immunotherapy. The trial is being performed at multiple sites in the US. The product is based on the company’s novel Versamune® vector which was shown in preclinical studies to be very safe and effective in treating cancer.
June 2012: PDS grants Merck KGaA license to utilize Versamune™ in cancer vaccines. PDS granted Merck KGaA, Darmstadt, Germany, an exclusive worldwide license to utilize PDS’s novel Versamune™ nanotechnology platform in two of Merck’s investigational antigen-specific cancer immunotherapies.

Welcome to PDS Biotechnology Corporation

PDS Biotechnology is a clinical stage Biopharmaceutical Company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and other disease areas such as infectious disease.

To see how Versamune™ works, please click here.

Stimulating, and training the immune system to recognize and kill cancer cells has been demonstrated to be one of the most promising approaches to treating various types of cancer.

It is now well established that cancers can be classified by the type of unique protein “antigen” expressed by the particular cancer cells. PDS Biotechnology is focusing its initial product pipeline on a number of cancers which express a few well-characterized cancer antigens. For example, the company’s first cancer immunotherapy, PDS0101 treats cancers caused by infection with the human papillomavirus. Such cancers include cervical, oral, anal, vulvar and penile cancers, as well as intraepithelial neoplasia. . The PDS0101 product is currently in Phase I human clinical trials at multiple sites in the US.

Other debilitating cancers potentially addressable by PDS’s product technology include ovarian cancer, pancreatic cancer, melanoma, leukemia, and multiple myeloma.

PDS Biotechnology has developed a simple and synthetic nanoparticle platform vector known as Versamune®. This novel and superior nanotechnology platform is very effective in training the immune system to recognize and fight the particular disease (see video on how Versamune® works). To do so, the unique protein antigen from the particular cancer type is formulated and injected with Versamune®. In pre-clinical studies very effective and superior treatment of advanced aggressive cancers with low doses of the Versamune®-based products has been demonstrated. The preclinical and on-going clinical studies have also demonstrated that the Versamune®-based cancer immunotherapies are exceptionally safe and well tolerated. Versamune® is the first synthetic immunotherapy and immunotherapy vector to demonstrate potent disease killing T-cell responses without the need for the addition of immune activators known as adjuvants.

PDS Biotechnology is initially applying the Versamune® vector to the treatment of HPV related cancers such as cervical cancer, oral cancer and cervical intraepithelial neoplasia (pre-cervical cancer). PDS’s lead HPV cancer immunotherapy product, PDS0101 is currently in phase 1 human clinical trials at multiple clinics within the US.

In 2012, PDS signed a licensing agreement with a global pharmaceutical company, Merck KGaA, granting it a license to utilize PDS Biotechnology’s patented Versamune® technology in the development of novel cancer immunotherapies.